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Abstract 
Background: Malaria, HIV/AIDS, and tuberculosis endemic areas show considerable geographical overlap, leading to 
incidence of co-infections. This requires treatment with multiple drugs, potentially causing adverse drug–drug inter-
actions (DDIs). As anti-malarials are generally positively charged at physiological pH, they are likely to interact with 
human organic cation transporters 1 and 2 (OCT1 and OCT2). These transporters are involved in the uptake of drugs 
into hepatocytes and proximal tubule cells for subsequent metabolic conversion or elimination. This efflux of cationic 
drugs from hepatocytes and proximal tubule cells into bile and urine can be mediated by multidrug and toxin extru-
sion 1 and 2-K (MATE1 and MATE2-K) transporters, respectively.
Methods: Here, the interaction of anti-malarials with these transporters was studied in order to predict potential 
DDIs. Using baculovirus-transduced HEK293 cells transiently expressing human OCT1, OCT2, MATE1 and MATE2K 
uptake and inhibition was studied by a range of anti-malarials.
Results: Amodiaquine, proguanil, pyrimethamine and quinine were the most potent inhibitors of 4-(4-(dimethyl-
amino)styryl)-N-methylpyridinium iodide (ASP) transport, a known substrate of OCT1/2, resulting in half maximal 
inhibitory concentrations  (IC50) of 11, 13, 1.6, and 3.4 µM, respectively. Only quinine had a drug–drug index higher 
than the cut-off value of 0.1 for OCT2, therefore, in vivo pharmacokinetic studies focusing on DDIs involving this com-
pound and other OCT2-interacting drugs are warranted. Furthermore, proguanil appeared to be a substrate of OCT1 
and OCT2 with affinities of 8.1 and 9.0 µM, respectively. Additionally, MATE1 and MATE2-K were identified as putative 
transport proteins for proguanil. Finally, its metabolite cycloguanil was also identified as an OCT1, OCT2, MATE1 and 
MATE2-K substrate.
Conclusion: Anti-malarials can reduce OCT1 and OCT2 transport activity in vitro. Furthermore, proguanil and 
cycloguanil were found to be substrates of OCT1, OCT2, MATE1 and MATE2-K, highlighting the importance of these 
transporters in distribution and excretion. As these compounds shares substrate overlap with metformin DDIs can be 
anticipated during concurrent treatment.
Keywords: Proguanil, Cycloguanil, OCT1, OCT2, MATE1, MATE2-K, Anti-malarial, SLC
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
In 2015, there were over 200 million cases of malaria, 
causing more than 400,000 deaths [1]. To treat 
uncomplicated malaria infections, the World Health 
Organization (WHO) recommends the use of arte-
misinin-based combination therapy (ACT), consist-
ing of an artemisinin-derivative and partner drug that 
has a longer half-life [2]. The use of a variety of differ-
ent drugs, like anti-malarials taken during pregnancy 
or for prophylaxis or Plasmodium vivax relapse preven-
tion, creates a substantial pool of drugs. Considering the 
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geographical overlap with HIV/AIDS and tuberculosis 
(TB), co-infections could occur. As there are multiple 
anti-retrovirals (ARV), anti-TB and anti-malarials avail-
able for treatment, there is considerable risk for adverse 
drug–drug interactions (DDIs) if used concomitantly. 
These DDIs might lead to under- or overexposure of co-
administered drugs potentially causing either treatment 
failure or toxicity. Although DDIs between current co-
treatment of HIV and malaria have been predicted to 
be low [3], recent studies showed altered anti-malarial 
plasma concentrations upon ARV treatment [4–6]. Little 
is known about the potential interaction between anti-
malarials and the anti-TB drugs rifampicin and rifabutin 
[7], although it has been shown that rifampicin increases 
the clearance of quinine [8].
DDIs frequently occur at the level of biotransforma-
tion by cytochrome P450 enzymes in the liver [9], but 
membrane transport proteins can also be involved [10]. 
Previously, the potential treatment implications due to 
possible competition of anti-malarial and antiretroviral 
DDIs for cellular efflux via ATP binding cassette (ABC) 
transporters was brought forward [11]. Here, the inter-
action with organic cation transporters was studied, as 
anti-malarials are positively charged at physiological pH. 
Transport proteins belonging to the solute carrier (SLC) 
family are important for the elimination of drugs, con-
tain members that mainly import cations and have been 
linked to DDIs. Organic cation transporters (OCT) 1 and 
OCT2 are cellular uptake transporters belonging to the 
solute carrier (SLC) family, which are mainly expressed 
in liver and kidney [12] and within these organs localize 
to the basolateral membrane of hepatocyte and proxi-
mal tubule cells, respectively [13, 14]. Other important 
SLCs implicated in the transport of cationic drugs are 
multidrug and toxin extrusion (MATE) protein 1 and 
MATE2-K. They are primarily located to the apical side 
of proximal tubule cells (both) [15, 16] and hepatocytes 
(MATE1) [15], where they export drugs into the urine 
and bile, respectively. As OCT and MATE transport-
ers are important for the cellular uptake and export of 
drugs, interaction with these transporters could lead to 
unwanted adverse effects. Therefore, it is important to 
address interactions of anti-malarials with these trans-
porters, in order to avoid potential drug–drug interac-
tions in future therapy.
The inhibitory potential of eleven anti-malarials (amo-
diaquine, artemisinin, atovaquone, chloroquine, dihy-
droartemisinin, lumefantrine, mefloquine, primaquine, 
proguanil, pyrimethamine, and quinine) on human 
OCT1 and OCT2 transport activity was studied using 
HEK293 cells, in which these transporters were over-
expressed by baculovirus transduction. Anti-malarials 
(25–50  μM) that inhibited transport activity by more 
than 67% were selected for further determination of 
their half maximal inhibitory concentration  (IC50). 
Furthermore, it was determined which anti-malarials 
are potential OCT1 or OCT2 substrates and whether 
MATE1 or MATE2-K could play a role in the cellular 
efflux of these substrates.
Methods
Materials
Human embryonic kidney (HEK293) cells transiently 
expressing (a combination of ) human transporters 
of interest [organic cation transporter 1 or 2 (OCT1; 
SLC22A1 or OCT2; SLC22A2), multidrug and toxin 
extrusion protein 1 or 2-K (MATE1; SLC47A1 or 
MATE2-K; SLC47A2)], or enhanced yellow fluorescent 
protein (eYFP) were obtained from PharmTox (Nijmegen, 
The Netherlands).
BioCoat poly-d-lysine coated 24- and 96-wells plates 
were purchased from Becton–Dickinson B.V. (Breda, 
The Netherlands). Dulbecco’s Modified Eagle’s Medium 
(DMEM)  +  GlutaMAX-I, Hank’s balanced salt solu-
tion (HBSS) and 4-(4-(dimethylamino)styryl)-N-methyl-
pyridinium iodide (ASP; ≥  95% purity) were purchased 
from Life Technologies Europe B.V. (Bleiswijk, The 
Netherlands). Fetal bovine serum was purchased from 
Greiner Bio-One B.V. (Alphen a/d Rijn, The Nether-
lands). Sodium butyrate, amodiaquine dihydrochloride 
dehydrate (AQ; analytical standard), artemisinin (ART; 
98% purity), atovaquone (ATO; ≥  98% purity), chlo-
roquine diphosphate (CQ; ≥  98% purity), dihydroar-
temisinin (DHA; ≥  97% purity), lumefantrine (LUM; 
≥  98% purity), mefloquine hydrochloride (MQ; ≥  98% 
purity), primaquine diphosphate (PQ; 98% purity), pro-
guanil hydrochloride (PG; ≥  95% purity), pyrimeth-
amine (PYR; 98.8% purity), quinine (QN; ≥  98% purity) 
and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) were purchased from Sigma-Aldrich Chemie 
B.V. (Zwijndrecht, The Netherlands). Cycloguanil (CG; 
95% purity) was purchased from Aurum Pharmatech 
(Franklin Park, NJ, United States). N-methyl-quinidine 
(NMQ) was purchased from Solvo Biotechnology (Sze-
ged, Hungary). Bovine serum albumin fraction V (BSA) 
was purchased from Roche Diagnostics Nederland B.V. 
(Almere, The Netherlands). The Victor X3 multimode 
plate reader was purchased from PerkinElmer Neder-
land B.V. (Groningen, The Netherlands). Bio-Rad pro-
tein assay was purchased from Bio-Rad laboratories Inc. 
(Veenendaal, The Netherlands). The acquity ultra perfor-
mance liquid chromatography (UPLC) and Xevo TQ-S 
micro mass spectrometer was purchased from Waters 
(Milford, MA, USA). Finally, the HSS T3 analytical col-
umn and VanGuard HSS T3 pre-column were purchased 
from Waters (Dublin, Ireland).
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HEK293 cell culture and transduction
HEK293 cells were modified to transiently express 
(a combination of ) human OCT1, OCT2, MATE1, 
MATE2-K, or eYFP. Briefly, cDNA of the respective genes 
was cloned downstream of a CMV promoter into a bacu-
lovirus, of which passage three was used to transduce 
HEK293 cells. These cells were seeded in poly-d-lysine 
coated 24- or 96-wells plates and grown in a 37 °C incu-
bator at 5%  CO2. Growth was initiated at ~  25% con-
fluency using 375 or 125  μL cell and complete medium 
(DMEM +  GlutaMAX™-I supplemented with 10% fetal 
bovine serum) suspension per well, respectively. After 
24  h, cells were transduced with 30  µL virus (10  µL 
virus  +  20  µL complete medium in case of 96-wells 
plates) or 2 ×  15 µL virus for cells that required simul-
taneous expression of two transporters. Finally, 195  µL 
sodium butyrate (45 µL for 96-wells plates) was added to 
a final concentration of 2 mM to enhance protein expres-
sion [17].
Cellular transport inhibition assays
AMO (10 mM), ASP (1 mM), CQ (10 mM), PQ (10 mM) 
and PG (10  mM) were dissolved in MilliQ water. ART 
(10 mM), ATO (10 mM), DHA (10 mM), LUM (10 mM), 
MQ (10  mM), NMQ (20  mM), PYR (10  mM), QN 
(10 mM) were dissolved in DMSO. All compound stocks 
were stored at − 20  °C. Inhibition of OCT1- or OCT2-
mediated ASP uptake by anti-malarials was performed in 
poly-d-lysine coated 96-wells plates  2 or 3  days follow-
ing HEK293 cell transduction. In short, cells were washed 
with 125 µL 37 °C HBSS containing 10 mM HEPES, pH 
7.4. Then, a 50  µL mixture of ASP (10  µM) and anti-
malarial compound (25, 50 or 100  µM) in HBSS buffer 
(pH 7.4) was added to each well and incubated for 10 min 
at 37  °C. ASP transport was stopped by washing with 
125 µL ice-cold HBSS-HEPES buffer supplemented with 
0.5% BSA. Following a second wash with 125 µL ice-cold 
HBSS-HEPES buffer, cells were lysed with 125  µL 1  M 
NaOH and ASP was excited at a wavelength of 485 nm 
and fluorescence was detected at an emission wavelength 
of 535  nm using the Victor X3 multimode plate reader. 
Anti-malarial inhibition of OCT1- or OCT2-mediated 
ASP uptake was corrected for background signal (eYFP-
transduced cells; mock-transduced), normalized to 
protein content using the Bio-Rad protein assay and rep-
resented as relative ASP uptake after fixing solvent con-
trols to 100%. The mean ±  standard error of the mean 
(SEM) of three independent experiments performed in 
triplicate were plotted in GraphPad Prism version 5.03 
(GraphPad Software, Inc., La Jolla, CA, USA) and signifi-
cantly reduced ASP uptake was determined using a one-
way ANOVA with Dunnett’s post test.
Concentration-dependent inhibition was assessed of 
anti-malarial compounds that inhibited ASP uptake by 
more than 67% in the initial screens. For each compound, 
a range of seven concentrations was used to determine 
the concentration at which ASP uptake was inhibited 
half maximally  (IC50). At least three independent experi-
ments (4 for QN) were performed for each drug in trip-
licate as described above. Inhibition curves were plotted 
by nonlinear regression analyses of the data using Graph-
Pad Prism version 5.03. Minimum uptake was set to be 
greater than 0% and the curve-fitted top within each 
experiment was adjusted to 100% as follows: each uptake 
percentage value was multiplied by 100/top in order to 
let the curve fit start at 100% at the lowest drug concen-
tration. To generate the final dose–response inhibition 
curve per anti-malarial, percentage of uptake was aver-
aged for each drug concentration per experiment and the 
resulting mean  ±  SEM corresponding to three or four 
independent experiments were plotted.
DDI index calculation
In order to predict whether future pharmacokinetic stud-
ies are recommended to study transporter inhibition 
in  vivo, DDI indices were calculated by using the for-
mula DDI index =  fraction unbound *  Cmax/IC50 with a 
cut-off value of 0.1 [18]. As  Cmax the (geometric) mean or 
median maximum plasma concentrations obtained from 
previous in vivo pharmacokinetic studies after therapeu-
tic dosing was used.
Cellular import and export assays
HEK293 cells were seeded in 24-wells poly-d-lysine 
coated plates and transduced the subsequent day with 
OCT1 or OCT2 as described above. Three days follow-
ing transduction, OCT1- or OCT2-mediated uptake of 
ten anti-malarials (AMO, ART, ATO, CQ, DHA, LUM, 
MQ, PQ, PG, and QN) was performed. NMQ served as 
a positive substrate for both OCT1 and OCT2 import 
[19]. In short, cells were washed with 400 µL 37 °C HBSS-
HEPES buffer followed by adding 150  µL HBSS buffer 
with 10  µM anti-malarial or NMQ to each well. After 
incubation for 15  min at 37  °C, import was stopped by 
washing with 400  µL ice-cold HBSS-HEPES buffer sup-
plemented with 0.5% BSA. Following a second wash with 
400  µL ice-cold HBSS-HEPES buffer, cells were lysed 
with 200 µL 50% (v/v) MeOH and 0.1% (v/v) formic acid 
(HCOOH) in water and samples were sent for quantifi-
cation by mass spectrometry analysis (see “LC–MS/MS 
quantification of anti-malarials” section). Anti-malarial 
import mediated by OCT1 or OCT2 was performed in 
two independent experiments in triplicate per drug and 
normalized to background (mock-transduced cells). 
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Percentage of anti-malarial uptake (compared to back-
ground control) was plotted as mean (6 values) ±  SEM 
in GraphPad Prism version 5.03 and drugs with at least 
a twofold increase versus background were selected for 
further analysis.
The affinity  (KM) and maximum transport rate  (Vmax) 
for OCT1 and OCT2 of PG were determined by analys-
ing concentration-dependent uptake data from three 
independent experiments. The experimental setup was 
similar to the cellular import assay, except that a range 
of four concentrations (2.0, 3.9, 7.8 and 16  µM) and an 
incubation time of 1 min was used to determine the  KM 
of proguanil. The Michaelis–Menten curve was plotted 
as mean ± SEM in GraphPad version 5.03 after fixing the 
 Vmax of each individual experiment to 100% and subtract-
ing mock-transduced background for each concentration 
used.
Import and export of PG and cycloguanil (CG) was 
assessed by single and double transduced HEK293 cells. 
In short, HEK293 cells seeded in 24-wells plates as 
described, were transduced separately with eYFP, OCT1, 
OCT2, MATE1 or MATE2-K, or with combinations of 
these viruses. Following the same procedure as for the 
cellular import assay described above, the import of 
100  µM PG and CG was measured after 5  min incuba-
tion and data was plotted as mean pmol/mg/min ± SEM. 
For export (following OCT1 uptake) of 1  µM PG after 
1  min of transport at pH 7.4, percentage of remain-
ing cellular PG (compared to background) was plotted 
as mean  ±  SEM in GraphPad version 5.03. Significant 
reduction in uptake (i.e. export by MATEs) was deter-
mined using ln transformation and a one-way repeated 
measures ANOVA with Dunnet’s post test.
Liquid chromatography–tandem mass spectrometry (LC–
MS/MS) quantification of anti‑malarials
Anti-malarial concentration in the cell lysates was quan-
tified using an LC–MS/MS system consisting of a UPLC, 
a binary solvent manager, a vacuum degasser and an 
autosampler, coupled to a Xevo TQ-S micro triple quad-
rupole mass spectrometer. Liquid chromatographic 
separation of the samples (stored at 10 °C; injection vol-
ume of 10  µL) was performed at 40  °C using a HSS T3 
analytical column (1.8 μm; 100 × 2.1 mm) coupled to a 
VanGuard HSS T3 pre-column (1.8  µm; 5  ×  2.1  mm). 
The mobile phase (run time: 10  min) consisted of sol-
vent A [20 mM ammonium formate and 0.5% (v/v) for-
mic acid (HCOOH) in water] and solvent B [0.5% (v/v) 
formic acid (HCOOH) in acetonitrile] using the follow-
ing gradient with a flow of 200 µL/min: 0–0.5 min, 50% 
A; 0.5–4.5  min, 5% A; 4.5–10  min, 50% A. Electrospray 
ionization (ESI) was operated at a capillary voltage of 
+ 1.0 kV and desolvation and source temperatures of 600 
and 150  °C, respectively. Nitrogen was used as desolva-
tion gas with a gas flow of 1000 L/h. Argon was used as 
collision gas at a pressure of 1.5 mTorr. Positive ion mode 
was used with selected reaction monitoring (SRM) for 
the quantitative analysis of AMO, ART, ATO, CQ, CG, 
DHA, LUM, MQ, PQ, PG, and QN. The peak area of the 
most abundant product ion was used for quantification. 
Ions with their corresponding mass/charge (m/z) ratio 
are shown in Table 1.
Results
Inhibition of OCT1‑ and OCT2‑mediated ASP transport 
by anti‑malarials
Using the baculovirus transduction system as described 
previously [11], OCT1 and OCT2 were transiently 
expressed in HEK293 cells. These cells were used to 
study the inhibitory effect of eleven anti-malarials 
(AMO, ART, ATO, CQ, DHA, LUM, MQ, PQ, PG, PYR, 
and QN) on OCT1- and OCT2-mediated ASP transport. 
Uptake of ASP by mock-transduced cells served as a 
negative control, which was used for background correc-
tion. Simultaneous incubation of 10  µM ASP, a known 
substrate of OCT1 [20] and OCT2 [21], and 50 µM anti-
malarial drug (25 µM ATO and LUM, due to precipita-
tion beyond these concentrations; 100 µM QN was used 
as positive control) for 10  min at 37  °C resulted in dif-
ferent inhibition profiles for OCT1 and OCT2. OCT1-
mediated ASP transport in HEK293-transduced cells 
was only partially inhibited to 49 ± 3% by 100 µM QN 
(p  <  0.05) and even stimulated by MQ to 150  ±  21% 
(p  <  0.05) (Fig.  1a). Four other anti-malarials, AQ, PQ, 
PG, and PYR inhibited ASP uptake at a concentration of 
50 µM for more than 30%, to a relative uptake of 67 ± 4, 
59 ± 3, 60 ± 7, and 59 ± 6%, respectively, although these 
were non-significant inhibitions. In OCT2-transduced 
Table 1 Mass fragments of the most abundant ions for the 
detection of anti-malarials by LC–MS/MS
Compound name Precursor ion (m/z) Product ion (m/z)
Amodiaquine 356.1 283.0
Artemisinin 282.0 162.9
Atovaquone 365.0 337.0
Chloroquine 320.1 247.1
Cycloguanil 252.1 58.0
Dihydroartemisinin 221.0 163.1
Lumefantrine 530.1 512.1
Mefloquine 379.1 361.1
N-Methyl-quinidine 339.1 160.0
Primaquine 260.1 243.1
Proguanil 254.0 170.0
Quinine 325.1 307.1
Page 5 of 12van der Velden et al. Malar J  (2017) 16:422 
HEK293 cells, ASP uptake was reduced to 61 ± 13 and 
60 ± 7% by ART and PQ, respectively. AQ, CQ, PG, PYR, 
and QN significantly reduced ASP uptake to 12.1 ± 0.6% 
(p  <  0.001), 48 ±  11% (p  <  0.05), 19 ±  7% (p  <  0.001), 
6 ± 2% (p < 0.001), and 3 ± 6% (p < 0.001), respectively 
(Fig. 1b).
a b
c d
e f
Fig. 1 Inhibition of OCT1 and OCT2 by anti-malarials. The inhibition of OCT1 (a) and OCT2 (b) by eleven anti-malarials (AQ, ART, ATO, CQ, DHA, LUM, 
MQ, PQ, PG, PM, and QN) at a concentration of 50 μM (except for ATO, LUM: 25 μM, and QN: 100 μM) was studied using 10 μM ASP as a substrate 
during 10 min incubation at 37 °C. Percentage of ASP uptake was expressed relative to solvent controls, which were fixed at 100%. Anti-malarials 
showing an inhibitory potential > 67% (grey bars) were selected for  IC50 determination. Concentration-dependent inhibition of OCT2-mediated 
ASP (10 μM) uptake during 10 min incubation at 37 °C resulted in  IC50 values of 11 μM (95% CI 6–22 µM), 13 μM (95% CI 10–17 µM), 1.6 μM (95% CI 
1.0–2.5 µM), and 3.4 μM (95% CI 1.1–11 µM) for AQ (c), PG (d), PM (e), and QN (f), respectively. *p < 0.05, ***p < 0.001
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The anti-malarials that most potently inhibited OCT1- 
and/or OCT2-mediated ASP import (more than 67%) 
were selected for further analysis by determining their 
 IC50-values. Using a larger concentration range, inhibi-
tion of OCT2-mediated transport of 10 µM ASP by AQ, 
PG, PYR, and QN was assessed using a similar set-up as 
above. Sigmoidal inhibition curves were generated by 
plotting ASP uptake rates as percentage of control versus 
increasing drug concentrations (Fig. 1c–f). This resulted 
in the strongest inhibition by PYR and QN with low 
micromolar  IC50 concentrations of 1.6 µM (95% CI 1.0–
2.5  µM) and 3.4  µM (95% CI 1.1–11  µM), respectively. 
These were closely followed by  IC50-concentrations of 
11 µM (95% CI 6–22 µM) and 13 µM (95% CI 10–17 µM) 
for AQ and PG, respectively. In order to assess the clini-
cal relevance of these values, DDI indices were calcu-
lated, and a cut-off value of 0.1 was applied to indicate 
the requirement for future in vivo pharmacokinetic stud-
ies [18]. Based on reported  Cmax and unbound fraction 
values, only QN, with a DDI index of 1.1, fulfilled the cri-
terion (Table 2).
OCT1‑ and OCT2‑mediated proguanil and cycloguanil 
uptake
Next, the potential substrates of OCT1 or OCT2 
amongst the tested anti-malarials (AMO, ART, ATO, 
CQ, DHA, LUM, MQ, PQ, PG, and QN) were identi-
fied. Uptake of anti-malarials (10  µM) in HEK293 cells 
expressing these transporters was determined follow-
ing 15 min incubation at 37 °C by LC–MS/MS after cell 
lysis. Uptake was represented as percentage of mock-
transduced HEK293 control cells. Anti-malarials with 
more than twofold increase in uptake of control versus 
transporter cells were regarded as potential substrates. 
NMQ was used as a positive OCT1 and OCT2 control 
substrate. NMQ was taken up by OCT1 and OCT2 as 
expected. Only one anti-malarial, PG, showed an uptake 
of more than 200% of the control value. PG was taken 
up by OCT1 (301  ±  25% of control) as well as OCT2 
(207 ± 17%) into HEK293 cells (Fig. 2a, b).
Next, the transport kinetics of PG uptake by OCT1 and 
OCT2 (eYFP-transduced cells served as background con-
trol) were studied. Concentration-dependent uptake of 
PG was measured during 1 min of incubation at 37 °C and 
its affinity  (KM) and maximum transport rate  (Vmax) were 
determined. Uptake of PG by OCT1 was characterized 
by a  KM of 8.1 ± 1.6 µM and  Vmax of 1840 ± 510 pmol/
mg protein/min. PG affinity for OCT2 was similar with 
a  KM of 9.0 ± 1.1 µM and  Vmax of 4440 ± 1500 pmol/mg 
protein/min (Fig. 2c, d).
As PG is metabolized in the liver to its active metab-
olite CG by CYP2C19 [22], CG transport by OCT1 or 
OCT2 was investigated. Uptake studies of CG were per-
formed similarly as with the previous anti-malarials, with 
a 5  min incubation time at 37  °C. This resulted in sig-
nificant uptake by OCT1 and OCT2 into HEK293 cells 
(Fig. 2e).
MATE1 and MATE2‑K‑mediated proguanil and cycloguanil 
transport
As PG is likely imported into hepatocytes and proximal 
tubule cells via OCT1 and OCT2, it was tested whether 
this compound could be exported by the extrusion trans-
porters MATE1 and MATE2-K. These transporters are 
able to export and import compounds depending on the 
physiological conditions. For this purpose, HEK293 cells 
were transduced with eYFP (mock), MATE1, or MATE2-
K. Uptake was represented as percentage of eYFP con-
trol cells. Incubation of 100 µM PG for 5 min resulted in 
small significant uptake by MATE1 (Fig. 3a).
To study PG export capacity of MATE1 and MATE2-
K, HEK293 cells were co-transduced with eYFP (mock) 
Table 2 Calculated DDI indices of the four most potent OCT2 inhibitors
a (Geometric) mean or median maximum plasma concentrations as determined in in vivo pharmacokinetic studies
b DDI index calculated by dividing the unbound  Cmax by the  IC50 concentration. A DDI index cut-off value ≥ 0.1 is believed to indicate the requirement for future 
in vivo pharmacokinetic studies [18]
c In Ugandan children aged 5–13 years with uncomplicated malaria
d In Thai children with uncomplicated multidrug-resistant falciparum malaria
e In patients with acute falciparum malaria
f In adult patients with uncomplicated falciparum malaria
g In Thai patients with falciparum malaria
Compound name Cmax (ng/mL)
a Cmax (µM) Unbound fraction IC50 (µM) DDI  index
b
Amodiaquine 5.2c [45] 0.015 0.1 [46] 11 0.0001
Proguanil 306d [47] 1.2 0.25 [39] 13 0.02
Pyrimethamine 281e [48] 1.1 0.06 [49] 1.6 0.04
Quinine 11430f [50] 35 0.11g [36] 3.4 1.1
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c
e
d
Fig. 2 Anti-malarial uptake by OCT1 and OCT2, and uptake characteristics of PG. Uptake of 10 anti-malarials (AQ, ART, ATO, CQ, DHA, LUM, MQ, 
PQ, PG, and QN) at a concentration of 10 μM by OCT1 (a) or OCT2 (b) was measured after 15 min of incubation at 37 °C. NMQ served as a positive 
substrate for both transporters. Uptake was measured in pmol/mg protein/min and expressed as percentage of eYFP control. Anti-malarials show-
ing at least a twofold uptake (grey bars) were selected for further analysis. Transport kinetics of PG during 1 min incubation at 37 °C resulted in a 
 KM of 8.1 ± 1.6 µM and  Vmax of 1840 ± 510 pmol/mg/min for OCT1 (c) and a  KM of 9.0 ± 1.1 µM and  Vmax of 4440 ± 1500 pmol/mg/min for OCT2 
(d). Uptake of 100 µM CG for 5 min showed a significantly higher CG uptake for OCT1 (139 ± 9 pmol/mg/min) and OCT2 (118 ± 18 pmol/mg/min) 
compared to the control (9.7 ± 0.3 pmol/mg/min) (e). ***p < 0.001
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and OCT1, OCT1 and MATE1, or OCT1 and MATE2-
K. Uptake was represented as percentage of eYFP control 
cells. Incubation of 1 µM PG for 1 min resulted in eight-
fold uptake by OCT1 (850  ±  60% of control) (Fig.  3b). 
This uptake was similar in cells expressing OCT1 and 
MATE1 (780  ±  70% of control) simultaneously. How-
ever, uptake was significantly reduced in cells expressing 
OCT1 and MATE2-K (470 ±  80% of control, p < 0.01), 
indicating that approximately 50% of PG was exported by 
MATE2-K as compared to eYFP/OCT1 transduced cells.
Finally, CG was analysed as a potential MATE1 and 
MATE2-K substrate by transfecting HEK293 cells with 
these transporters. Incubation of 100 µM CG for 5 min 
resulted in significant uptake by MATE1 (40 ± 9 pmol/
mg/min) and MATE2-K (56  ±  15  pmol/mg/min) com-
pared to control cells (11.8 ± 0.9 pmol/mg/min) (Fig. 3c). 
This highlights the involvement of MATE1 and MATE2-
K in excretion of PG and its metabolite CG.
Discussion
In this study, the focus was on the interaction of anti-
malarial drugs with the organic cation transporters 
OCT1, OCT2, MATE1 and MATE2-K. In  vitro, OCT1 
activity was not affected by any of the tested anti-malar-
ials, while OCT2 was inhibited in the low micromolar 
range by AQ, PG, PYR and QN. These compounds all 
share structural features with other OCT2 inhibitors as 
predicted previously [21].
Inhibition of OCT2 by AQ and PG has not been 
reported previously. The calculated DDI indices of both 
drugs were below 0.1, indicating that clinically relevant 
DDIs related to OCT1 and OCT2 transport are unlikely 
to occur, but should not be fully excluded as local con-
centrations at the site of the transporter might be higher 
compared to systemic levels. Although it has been shown 
that co-administration of efavirenz (EFV), lopinavir 
(LPV)/ritonavir (RTV) or atazanavir/RTV with ATO/
PG cause a reduction in the AUC of both anti-malarials 
[4], the decrease in PG level was attributed to induction 
of CYP2C19 by EFV and LPV/RTV [23, 24]. In contrast, 
EFV has been shown to increase  Cmax levels of PG by 
47%, most likely caused by inhibition instead of induc-
tion of CYP2C19 metabolism, which was supported 
by a reduction in cycloguanil (CG) levels [5]. Another 
explanation for an increase in PG plasma concentra-
tion might be that EFV was also shown to be an inhibi-
tor (absolute  IC50 of 22  μM) of OCT1 [25] and it was 
demonstrated that PG is a substrate of OCT1. However, 
although maximum plasma concentrations of EFV reach 
13 μM [26], only about 0.22% is unbound (0.03 μM) [27], 
resulting in a DDI index for OCT1 well below 0.1, which 
makes an increase in the  Cmax of PG unlikely. The AUC 
of EFV has been shown to increase in two subjects in a 
a
b
c
Fig. 3 PG and CG uptake by MATE1 and MATE2-K. Uptake of 100 µM 
PG for 5 min for MATE1 (430 ± 110 pmol/mg/min) and MATE2-K 
(360 ± 90 pmol/mg/min) compared to the control (300 ± 40 pmol/
mg/min) in HEK293 transduced cells (a). Following co-transduction 
of eYFP and OCT1, after measuring uptake of 1 μM PG during 1 min 
incubation, PG was taken up for 850 ± 60% as compared to eYFP 
control cells. MATE1 was not capable of reducing OCT1-mediated PG 
uptake by exporting this anti-malarial, however, MATE2-K reduced PG 
uptake to 470 ± 80% of control, which is a relative decrease of 44% in 
uptake (b). Uptake of 100 µM CG for 5 min was significantly higher for 
MATE1 (40 ± 9 pmol/mg/min) and MATE2-K (56 ± 15 pmol/mg/min) 
compared to the control (11.8 ± 0.9 pmol/mg/min) (c). *p < 0.05, 
**p < 0.01, ***p < 0.001
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pharmacokinetic study upon simultaneous AQ/artesu-
nate treatment, resulting in increased hepatic transami-
nase levels [28]. Although we demonstrated that AQ 
inhibits OCT2, the calculated DDI index is very low. 
Hence, boosted EFV levels involving this transporter 
(and assuming that EFV is an OCT2 substrate) are highly 
unlikely.
PYR was shown to be the strongest inhibitor of OCT2 
activity with an  IC50 of 1.6 µM. Previously, PYR has been 
shown to reduce OCT2 activity by 60% at a concentra-
tion of 50  µM [29]. This is a substantial difference with 
the presented findings, but could be explained by differ-
ences in cell type (HEK293 vs. HeLa) and substrate (con-
centration) [ASP vs. metformin (MET)] used. Results 
from another group, studying inhibition of MET elimi-
nation by PYR [30], were more in accordance with ours. 
Using HEK293 cells stably expressing human OCT2, a 
 Ki value of 10 µM PYR for OCT2-mediated MET uptake 
was found. Although PYR was capable of increasing 
MET AUC at therapeutic dose, this effect was attributed 
to inhibition of MATE1 and MATE2-K, as their  Ki val-
ues were over 100-fold lower than the  Ki value for OCT2 
inhibition [30].
In a previous study with stably transfected OCT1 and 
OCT2 HEK293 cells, inhibition of N-[methyl-3H]4-phe-
nylpyridinium  ([3H]MPP+) uptake by QN resulted in  IC50 
concentrations of 13 and 23  µM for OCT1 and OCT2, 
respectively [31]. While QN was found to be more potent 
at inhibiting OCT1 [31], in this study QN was a more 
potent inhibitor of OCT2, which might be explained 
by a different choice of substrate. The presented results 
more closely resemble two other studies, that also used 
ASP as a substrate, and found that 20 µM QN inhibited 
OCT2 by 72% [21] and 100 µM QN inhibited OCT1 by 
60% [20]. In the current study, the highest reported DDI 
index was 1.1 for QN. While DDIs for QN have been 
described, and a potential role at the transport level by 
P-glycoprotein/ABCB1 inhibition was studied previously 
[11], until now clinically relevant interactions caused by 
QN inhibition of OCT2 have not been reported. A phar-
macokinetic study showed that concurrent administra-
tion with RTV resulted in a modest increase of  Cmax and 
AUC of QN [32]. Since RTV is not an OCT2 substrate 
[33], a transporter interaction with QN is unlikely. Inhi-
bition of CYP2D6 by QN was speculated to cause this 
effect. In addition, simultaneous RTV and QN adminis-
tration resulted in an approximately fourfold increase in 
 Cmax and AUC of QN, which might be due to CYP3A4 
interactions [32].
The DDI indices reported here should be interpreted 
with caution, as multiple factors may influence this value. 
Firstly, individual peak plasma concentrations in a dif-
ferent population may be substantially higher than the 
(geometric) mean or median shown in Table 2. Further-
more, the unbound fraction of a drug may alter depend-
ing on, e.g. plasma pH [34], pregnancy [35] and disease 
status. Indeed, in the case of QN treatment, increased 
intensity of malaria infection correlated with more 
plasma protein binding (lower unbound fraction) of 
QN [36, 37]. Still, as QN blood concentration rises with 
severity of disease [38], unbound QN concentrations may 
remain at a similar level due to a higher plasma protein 
binding [37].
PG was found to be the only anti-malarial substrate of 
OCT1 and OCT2, having similar  KM values of 8.1 and 
9.0 µM for both transporters, respectively. This highlights 
OCT1 as a likely liver uptake transporter for PG, where 
it is metabolized into its active metabolite CG (Fig.  4). 
Moreover, OCT2 seems to be involved in the extrusion of 
PG via the kidneys, where it is excreted into the urine for 
<  40% as well as its metabolites [39]. Similarly, CG also 
was shown to be a substrate of both OCT1 and OCT2, 
which requires further investigation. The latter trans-
porter seems to be involved in the renal elimination of 
CG as this compound can also be excreted into the urine 
[40].
In addition, when MATE1 and MATE2-K were trans-
duced in HEK293 cells this resulted in a small significant 
uptake of PG by MATE1. When CG was used as poten-
tial substrate, uptake by MATE1 and MATE2-K was 
clearly present. Furthermore, in order to study the ability 
of MATE1 and MATE2-K to efflux PG, co-transduction 
studies were performed. When MATE1 and MATE2-K 
were co-transduced with OCT1, only MATE2-K reduced 
the intracellular PG concentration to 56% of its initial 
value indicating export of PG by this transporter. Thus, 
both CG and PG are most likely substrates of MATE1 and 
MATE2-K, who secrete these compounds from the prox-
imal tubule into urine. Interestingly, PG shows structural 
similarity to MET (both contain guanidine fragments), 
a known MATE1 [41], MATE2-K [41], OCT1 [42], and 
OCT2 [43] substrate. It has been shown that polymor-
phisms in OCT1 can cause reduced liver uptake of MET 
[44], hence, these variants might also result in reduced 
hepatic PG uptake leading to less CG conversion. Addi-
tionally, as MET is the first-line drug of choice to treat 
type 2 diabetes (DMII), adverse drug interactions with 
PG may be anticipated, e.g. when the latter compound is 
used as prophylactic drug in travelers with DMII.
Conclusion
In the present study, the interaction of parent com-
pounds with transport proteins was investigated. As part 
of these anti-malarials undergo biotransformation in the 
body, their metabolites might also influence transport 
activity. Therefore, future research should focus on these 
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products as they might increase the DDI potential of 
their parent compound or have different targets that may 
cause separate DDIs.
In conclusion, anti-malarials can reduce OCT1 and 
OCT2 transport activity in  vitro. Only QN inhibited 
OCT2 at a therapeutic relevant dose with a DDI index 
above the 0.1 cut-off value, warranting in  vivo pharma-
cokinetic studies. However, many factors influence this 
value and, therefore, individual cases of DDI with other 
tested compounds cannot be excluded. While anti-malar-
ials and anti-retrovirals are often used concomitantly and 
may cause adverse DDIs, they most likely are not result-
ing from interactions with transporters described here 
due to differential substrate specificity for anti-retrovirals 
or low DDI indices. Furthermore, CG and PG were found 
to be substrates of OCT1, OCT2, MATE1 and MATE2-
K, highlighting the importance of these transporters in 
CG and PG distribution and excretion. As PG shares sub-
strate overlap with MET for OCT1, OCT2, MATE1 and 
MATE2-K, DDIs can be anticipated during concurrent 
treatment.
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